Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Andrea J, Bullock"'
Autor:
Daniel L. Hall PhD, Gloria Y. Yeh MD, MPH, Conall O'Cleirigh PhD, Jeffrey Peppercorn MD, MPH, Lynne I. Wagner PhD, John Denninger MD, PhD, Andrea J. Bullock MD, Helen R. Mizrach BS, Brett Goshe PhD, Tina Cheung BS, Raissa Li BS, Alexandros Markowitz BS, Elyse R. Park PhD, MPH
Publikováno v:
Global Advances in Health and Medicine, Vol 11 (2022)
Background For cancer survivors, there is a paucity of fear of recurrence (FOR) interventions that integrate empirically supported mind-body and psychological skills for managing FOR and are delivered in scalable formats. Objective To adapt an eviden
Externí odkaz:
https://doaj.org/article/f75961cbce5c4b31a3cdb2adf6de4204
Autor:
Rupal S. Bhatt, Roger A. Sabbadini, Manoj Bhasin, Sabina Signoretti, James W. Mier, Michael B. Atkins, David C. Alsop, Douglas Deutschman, Barbara Visentin, Kelli Moreno, Jiaxi Song, Harleen Shah, Marcella Callea, Andrea J. Bullock, Xiaoen Wang, Liang Zhang
Table S1: Plasma S1P levels in patients with RCC; Table S2: Table of ASL MRI values.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679cd8fd847d704422c517b1d333c8f7
https://doi.org/10.1158/1078-0432.22456143.v1
https://doi.org/10.1158/1078-0432.22456143.v1
Autor:
Rupal S. Bhatt, Roger A. Sabbadini, Manoj Bhasin, Sabina Signoretti, James W. Mier, Michael B. Atkins, David C. Alsop, Douglas Deutschman, Barbara Visentin, Kelli Moreno, Jiaxi Song, Harleen Shah, Marcella Callea, Andrea J. Bullock, Xiaoen Wang, Liang Zhang
Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell carcinoma (RCC). However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20cf7ff807f52d401d37aa642d876bc8
https://doi.org/10.1158/1078-0432.c.6523218
https://doi.org/10.1158/1078-0432.c.6523218
Autor:
Rupal S. Bhatt, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith Flaherty, Naomi B. Haas, Michael B. Atkins, David F. McDermott, Daniel Tamasauskas, Andrea J. Bullock, Judith Manola, Maneka Puligandla, Wenxin Xu
Purpose:The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on circulating cytokines in the ECOG-ACRIN 2805 (ASSURE) trial.Experimental Design:Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd626d06e452000fdcaf81cee5a3311c
https://doi.org/10.1158/1078-0432.c.6528116
https://doi.org/10.1158/1078-0432.c.6528116
Autor:
Andrew X. Zhu, Dan G. Duda, Rakesh K. Jain, Kohei Shigeta, Emilie Mamessier, Tai Hato, Eileen Regan, Caroline F. Dinicola, Anthony J. Afflitto, Aralee Galway, Michelle Knowles, Alona Muzikansky, Avinash Kambadakone, Jeffrey W. Clark, Matthew B. Yurgelun, Jill N. Allen, Andrea J. Bullock, Rebecca Miksad, Thomas A. Abrams, Hui Zheng, Lipika Goyal
Figure S1 is a schematic of lymphocytes shown as CD3+ cells against side scatter (SSC). Figure S2 is a Kaplan-Meier time-to-progression graph.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aac09adb55eeb2866688064160541dc
https://doi.org/10.1158/1078-0432.22474422
https://doi.org/10.1158/1078-0432.22474422
Autor:
Rupal S. Bhatt, Robert S. DiPaola, Janice P. Dutcher, Robert G. Uzzo, Keith Flaherty, Naomi B. Haas, Michael B. Atkins, David F. McDermott, Daniel Tamasauskas, Andrea J. Bullock, Judith Manola, Maneka Puligandla, Wenxin Xu
Supplemental Table 1: Catalog numbers for MSD assays Supplemental Figure 1: Hazard ratio for CXCL10 and DFS by treatment arm Supplemental Figure 2: Assessment of log-linearity for relationship between IP-10 and recurrence risk Supplemental Table 2: M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22725f540ce6119fca43b206fae8c846
https://doi.org/10.1158/1078-0432.22472090.v1
https://doi.org/10.1158/1078-0432.22472090.v1
Autor:
Manuel Hidalgo, Senthil K. Muthuswamy, Mark Callery, Tara S. Kent, Martin Smith, Tyler M. Berzin, Douglas Pleskow, Mandeep S. Sawhney, Robert Besaw, Roger B. Davis, Christine Lim, Supraja Narasimhan, Catherine Conahan, Mary Linton B. Peters, Benjamin Schlechter, Andrea J. Bullock, Bruno Bockorny, Jonah Cohen, Leo L. Tsai, Raul S. Gonzalez, Sofia Perea, Dipikaa Akshinthala, Ling Huang, Lakshmi Muthuswamy, Joseph E. Grossman
Supplementary Data from Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1260fc09a1c2717a2c1423956de7284d
https://doi.org/10.1158/1078-0432.22484078
https://doi.org/10.1158/1078-0432.22484078
Autor:
Andrew X. Zhu, Dan G. Duda, Rakesh K. Jain, Kohei Shigeta, Emilie Mamessier, Tai Hato, Eileen Regan, Caroline F. Dinicola, Anthony J. Afflitto, Aralee Galway, Michelle Knowles, Alona Muzikansky, Avinash Kambadakone, Jeffrey W. Clark, Matthew B. Yurgelun, Jill N. Allen, Andrea J. Bullock, Rebecca Miksad, Thomas A. Abrams, Hui Zheng, Lipika Goyal
Purpose:Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7e2b43bbbedb01a8b5b498b8558469
https://doi.org/10.1158/1078-0432.c.6528783
https://doi.org/10.1158/1078-0432.c.6528783
Autor:
Manuel Hidalgo, Senthil K. Muthuswamy, Mark Callery, Tara S. Kent, Martin Smith, Tyler M. Berzin, Douglas Pleskow, Mandeep S. Sawhney, Robert Besaw, Roger B. Davis, Christine Lim, Supraja Narasimhan, Catherine Conahan, Mary Linton B. Peters, Benjamin Schlechter, Andrea J. Bullock, Bruno Bockorny, Jonah Cohen, Leo L. Tsai, Raul S. Gonzalez, Sofia Perea, Dipikaa Akshinthala, Ling Huang, Lakshmi Muthuswamy, Joseph E. Grossman
Purpose:Pancreatic ductal adenocarcinoma (PDAC) remains a significant health issue. For most patients, there are no options for targeted therapy, and existing treatments are limited by toxicity. The HOPE trial (Harnessing Organoids for PErsonalized T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c2c3cab84e98173ebbc1888ec47fd08
https://doi.org/10.1158/1078-0432.c.6531320
https://doi.org/10.1158/1078-0432.c.6531320
Autor:
Bruno Bockorny, Lakshmi Muthuswamy, Ling Huang, Marco Hadisurya, Christine Maria Lim, Leo L. Tsai, Ritu R. Gill, Jesse L. Wei, Andrea J. Bullock, Joseph E. Grossman, Robert J. Besaw, Supraja Narasimhan, W. Andy Tao, Sofia Perea, Mandeep S. Sawhney, Steven D. Freedman, Manuel Hidalgo, Anton Iliuk, Senthil K. Muthuswamy
Publikováno v:
medRxiv
Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be9a56795ec8bd6bfdbbb0483831de1
https://doi.org/10.1101/2023.03.13.23287216
https://doi.org/10.1101/2023.03.13.23287216